Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
Sponsor: Beacon Therapeutics
Summary
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.
Official title: A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Key Details
Gender
All
Age Range
4 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2016-04-11
Completion Date
2026-07
Last Updated
2022-07-22
Healthy Volunteers
No
Conditions
Interventions
rAAV2tYF-PR1.7-hCNGB3
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Locations (8)
VitreoRetinal Associates
Gainesville, Florida, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp
Chicago, Illinois, United States
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Duke Eye Center, Duke University Medical Center
Durham, North Carolina, United States
Cincinnati Eye Institute
Cincinnati, Ohio, United States
Casey Eye Institute, Oregon Health and Sciences University
Portland, Oregon, United States